


DRY EYE DISEASE: IT MAY BE ALL IN YOUR EYELIDS

Meibomian Gland Dysfunction (MGD): Restore Gland Function Before It Regresses

What Is Meibomian Gland Dysfunction (MGD)?

Healthy Meibomian glands secrete oil with every blink. This oil, or lipid, serves as a critical component of a healthy tear film.


When the glands are not functioning correctly, it is called Meibomian Gland Dysfunction, or MGD. MGD is a leading cause of Dry Eye Disease and can be the source of dry eye symptoms, such as burning, stinging, and itching.



What Do Meibomian Glands Look Like?



NORMAL GLAND STRUCTURE



SHORTENED GLANDS & GLAND LOSS



SIGNIFICANT GLAND LOSS

One component of an evaluation for MGD can include an image of the eyelid, showing complete gland structure and Meibomian gland loss.

What Causes MGD?

MGD is caused by a change in the Meibomian glands. If left untreated, MGD is a chronic progressive condition and may worsen over time, leaving eyes feeling more irritated, inflamed, and dry.¹



While eye drops may temporarily soothe some symptoms of Dry Eye Disease, they do not remove Meibomian gland obstructions.

86%

of patients with a diagnosis of dry eye also had MGD, in one study.²

1 in 5

MGD patients may have no symptoms.

TREAT BEFORE SYMPTOMS BEGIN

Maintaining healthy function and structure of your Meibomian glands before you become symptomatic is key, as MGD is a chronic, progressive and obstructive condition.⁸⁻⁹

If you are diagnosed with MGD, there's something you can do about it. Early detection and treatment can minimize its long term negative impact.

REFERENCES

1. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. *Invest Ophthalmol Vis Sci.* 2011;52(4):1922-9. 2. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea.* 2012 May;31(5):472-478. 3. Duke University website. Immune response likely culprit in eyelid gland condition that causes dry eye. Found at: <https://dukeeyecenter.duke.edu/news-events/immune-response-likely-culprit-eyelid-gland-condition-causes-dry-eye>, July 2018. Accessed December 10, 2019. 4. American Optometric Association, Paraoptometric Resource Center, CPC Submission, T Petrosyan. Cosmetics and the eye: how your beauty products could be harming your eyes. Found at: <https://www.aoa.org/Documents/CPC%20SUBMISSION%20%20Cosmetics%20and%20the%20Eye%20How%20Your%20Beauty%20Products%20Could%20Be%20Harming%20Your%20Eyes.pdf>, 2018. Accessed December 10, 2019. 5. Machalinska A, Zakrzewska A, Adamek B, et al. Comparison of morphological and functional meibomian gland characteristics between daily contact lens wearers and nonwearers. *Cornea.* 2015;34(9):1098-104. 6. Uzunosmanoglu E, Mocan MC, Kocabeoglu S, Karakava J, Irkec M. Meibomian gland dysfunction in patients receiving long-term glaucoma medications. *Cornea.* 2016;35(8):1112-1116. Doi:10.1097/ico.0000000000000838 7. Cochener, et al. Prevalence of Meibomian Gland Dysfunction at time of Cataract Surgery. *Journal of Cataract and Refractive Surgery.* 2017 Feb;44(2):144-8. 8. Nichols KK, Hanlon SD, Nichols JJ. A murine model of characterizing glandular changes in obstructive meibomian gland dysfunction. *ARVO.* 2014. Abstract #13-A0002. 9. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. *Invest Ophthalmol Vis Sci.* 2011 Mar;52(4):1994-2005.

COMMON CONDITIONS THAT CONTRIBUTE TO MGD



Computer/
device use



Contact
lens wear



Allergies



Eye infections
(such as styes)³



Environment



Medications



Reading/
watching TV



Eye surgery



Glaucoma and
chronic eye diseases



Climate



Poor blinking



Makeup that can
clog glands⁴

SINGLE STUDIES SHOW MGD WAS PREVALENT IN

60%

of Contact
Lens Wearers⁵

79%

of Perimenopausal
Women

58%

of Diabetics

80%

of Glaucoma
Patients⁶

52%


of Cataract
Patients⁷

THE LIPIFLOW® PULSATION SYSTEM: A PROVEN TREATMENT FOR MGD

A treatment for your eyelids, this effective lid massage is typically done while resting in a chair in your doctor's office.

The LipiFlow® Treatment

- This is a safe and FDA-cleared,¹⁰ in-office procedure for the treatment of MGD.
- After an initial anesthetic eye drop, Meibomian glands are heated and then gently massaged to loosen the oil trapped within the glands.
- The contents are pushed up and out while protecting the delicate structure of the eye.



In patients with MGD, LipiFlow® can reduce ocular surface symptoms including symptoms of dry eye and blurred, poor vision.¹¹



In soft contact lens wearers with MGD, treating with LipiFlow® increased average comfortable lens wear time by 4 hours per day.¹²



Use of LipiFlow® prior to cataract surgery improved mean postoperative dry eye symptoms, a common side effect following cataract surgery.¹³

TREAT AN UNDERLYING CAUSE OF YOUR DRY EYES

Whether you have symptoms of MGD or are still asymptomatic, the time to talk to your doctor about the advantages of the LipiFlow® treatment is now.

Rx Only.

INDICATIONS AND IMPORTANT SAFETY INFORMATION for LipiFlow® Thermal Pulsation System

INDICATIONS: The LipiFlow® Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye. **CONTRAINDICATIONS:** Do not use the LipiFlow® System in patients with the following conditions. Use of the device in patients with these conditions may cause injury. Safety and effectiveness of the device have not been studied in patients with these conditions. **Ocular surgery within prior 3 months,** including intraocular, oculo-plastic, corneal or refractive surgery procedure. **Ocular injury within prior 3 months.** **Ocular herpes of eye or eyelid within prior 3 months.** **Active ocular infection** (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac, or eyelids including a hordeolum or sty). **Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months** (e.g., retinitis, macular inflammation, choroiditis, uveitis, iritis, scleritis, episcleritis, keratitis). **Eyelid abnormalities that affect lid function** (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis). **Ocular surface abnormality that may compromise corneal integrity** (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy). **PRECAUTIONS:** The Activator or Activator II (Disposable) may not fit all eyes, such as eyes with small palpebral fornices. Use of the LipiFlow® System in patients with the following conditions may result in reduced treatment effectiveness because these conditions may cause ocular symptoms unrelated to cystic meibomian glands and require other medical management. Safety and effectiveness of the device have not been studied in patients with these conditions. **Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis.** **Severe (Grade 3 or 4) eyelid inflammation** (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis). Patients with severe eyelid inflammation should be treated medically prior to device use. **Systemic disease conditions that cause dry eye** (e.g., Stevens-Johnson syndrome, vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis, sarcoidosis, leukemia, Riley-Day syndrome, systemic lupus erythematosus, Sjögren's syndrome). **Taking medications known to cause dryness** (e.g., isotretinoin (Accutane®) and systemic antihistamines). **Esthetic eyelid and eyelash procedures** (e.g., blepharoplasty, lash extensions, eyelid tattooing). In addition, the treatment procedure may loosen previously inserted punctal plugs, which may worsen the patient's dry eye symptoms. **ADVERSE EFFECTS:** Potential adverse effects that may occur as a result of the procedure include, but are not limited to, the onset or increase in: Eyelid/eye pain requiring discontinuation of the treatment procedure; Eyelid irritation or inflammation (e.g., edema, bruising, blood blister, dermatitis, hordeolum or chalazion); Ocular surface irritation or inflammation (e.g., corneal abrasion, conjunctival edema or conjunctival injection (hyperemia)); and Ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light). Potential serious adverse events (defined as permanent impairment or damage to a body structure or function or necessitates medical or surgical intervention to preclude permanent impairment or damage to a body structure or function) that are not anticipated because of the device mitigations to prevent occurrence include: Thermal injury to the eyelid or eye, including conjunctiva, cornea or lens; Physical pressure-induced injury to the eyelid; and Ocular surface (corneal) infection. **ATTENTION:** Reference the LipiFlow® Thermal Pulsation System Instructions for Use for a complete listing of indications, warnings, and precautions.

REFERENCES

10. K161357, 510K Summary. 11. Data on file. 12. Blackie CA, Carlson AN, Korb DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. *Curr Opin in Ophthalmol*. 2015 Jul;26(4):306-313. 13. Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, Kim T, Mehta JS, Messmer EM, Pepose J, Sangwan VS, Weiner et al. TFOS DEWS II iatrogenic report. *Ocul Surf*. 2017 Jul;15(3):511-538. 14. Internal data on file. 15. Blackie CA et al. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. *Clinical Ophthalmol*. 2016; 10:1385-1396. 16. Lane SS et al. A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction (MGD). *Cornea*. 2012;31(4):396-404.

©2020 Johnson & Johnson Surgical Vision, Inc. All other trademarks are the intellectual property of their respective owners. PP2020TS4038



With more than 400,000 treatments worldwide and growing, patients are experiencing proven benefits from the LipiFlow® Thermal Pulsation System.¹⁴

- ✓ Long-lasting results; many see the continued benefit for up to 12 months¹⁵
- ✓ No pain and/or discomfort reported for the vast majority of patients¹⁶

NOTE: Results with LipiFlow® can be experienced 6-8 weeks after treatment and may vary depending on the level of severity of MGD.¹⁶ Because LipiFlow® treats MGD, Dry Eye Disease symptoms are not expected to fully resolve with LipiFlow®. Dry Eye Disease is a multifactorial condition and may require additional treatment. Be sure to talk to your doctor about what's right for you.

LIPIFLOW®
THERMAL PULSATION

www.dryeyeandmgd.com